Positive PhII bladder cancer data fuel Telormedix's search for partner
This article was originally published in Scrip
Executive Summary
Swiss biopharmaceutical company Telormedix has completed a successful Phase II study of Vesimune (TMX-101) in patients with bladder cancer, and is now hoping to find a partner for the drug by the third quarter of this year.